1. Scrip
  2. >>R&D

Sanofi Looks To Build On Dupixent Dominance With OX40L Drug

Amlitelimab Could Be Dosed Less Frequently

 
• By Andrew McConaghie

Sanofi is looking to build its position in immunology, with a new anti-inflammatory candidate, amlitelimab, which could potentially help patients who do not respond to its blockbuster Dupixent.

Sanofi

Sanofi has unveiled positive Phase II data from amlitelimab in atopic dermatitis, backing up its belief that it could be a first and best-in-class novel therapy targeting the OX40 ligand.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

Could There Be A Cure For Cardiometabolic Disease? Novo Nordisk Foundation Wants To Help Academics Find Out

 
• By Andrew McConaghie

The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.